Infectious Diseases (except HIV/AIDS)

SARS-CoV-2 BA.4/5 Spike recognition and neutralization elicited after the third dose of mRNA vaccine
Alexandra Tauzin, Debashree Chatterjee, Katrina Dionne, Gabrielle Gendron-Lepage, Halima Medjahed, Yuxia Bo, Josée Perreault, Guillaume Goyette, Laurie Gokool, Pascale Arlotto, Chantal Morrisseau, Cécile Tremblay, Valérie Martel-Laferrière, Daniel E. Kaufmann, Gaston De Serres, Inès Levade, Marceline Côté, Renée Bazin, Andrés Finzi

medRxiv 2022.08.03.22278386; doi: https://doi.org/10.1101/2022.08.03.22278386

Add to Selected Citations
Viral Kinetics of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Omicron Infection in mRNA-Vaccinated Individuals Treated and Not Treated with Nirmatrelvir-Ritonavir
Eric Y. Dai, Kannon A. Lee, Audrey B. Nathanson, Ariana T. Leonelli, Brittany A. Petros, Taylor Brock-Fisher, Sabrina T. Dobbins, Bronwyn L. MacInnis, Amelia Capone, Nancy Littlehale, Julie Boucau, Caitlin Marino, Amy K. Barczak, Pardis C. Sabeti, Michael Springer, Kathryn E. Stephenson

medRxiv 2022.08.04.22278378; doi: https://doi.org/10.1101/2022.08.04.22278378

Add to Selected Citations
Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) is common in post-acute sequelae of SARS-CoV-2 infection (PASC): Results from a post-COVID-19 multidisciplinary clinic
H Bonilla, TC Quach, A Tiwari, AE Bonilla, M Miglis, P Yang, L Eggert, H Sharifi, A Horomanski, A Subramanian, L Smirnoff, N Simpson, H Halawi, O Sum-Ping, A Kalinowski, Z Patel, R Shafer, L. Geng

medRxiv 2022.08.03.22278363; doi: https://doi.org/10.1101/2022.08.03.22278363

Add to Selected Citations
QuaID: Enabling Earlier Detection of Recently Emerged SARS-CoV-2 Variants of Concern in Wastewater
Nicolae Sapoval, Yunxi Liu, Esther G. Lou, Loren Hopkins, Katherine B Ensor, Rebecca Schneider, Lauren B Stadler, Todd J Treangen

medRxiv 2021.09.08.21263279; doi: https://doi.org/10.1101/2021.09.08.21263279

Add to Selected Citations
Determinants of passive antibody efficacy in SARS-CoV-2 infection
Eva Stadler, Khai Li Chai, Timothy E Schlub, Deborah Cromer, Mark N Polizzotto, Stephen J Kent, Claire Beecher, Heath White, Tari Turner, Nicole Skoetz, Lise Estcourt, Zoe K McQuilten, Erica M Wood, David S Khoury, Miles P Davenport

medRxiv 2022.03.21.22272672; doi: https://doi.org/10.1101/2022.03.21.22272672

Add to Selected Citations
Longitudinal analyses after COVID-19 recovery or prolonged infection reveal unique immunological signatures after repeated vaccinations
Daisuke Hisamatsu, Akari Ikeda, Lisa Ito, Yasushi Matsushita, Makoto Hiki, Hirotake Mori, Yoko Tabe, Toshio Naito, Chihiro Akazawa

medRxiv 2022.08.03.22278353; doi: https://doi.org/10.1101/2022.08.03.22278353

Add to Selected Citations
Nano assembly of plasmonic probe-virus particles enabled rapid and ultrasensitive point-of-care SARS-CoV-2 detection
Younggeun Park, Byunghoon Ryu, Seungjune Ki, Mingze Chen, Xiaogan Liang, Katsuo Kurabayashi

medRxiv 2022.08.01.22278286; doi: https://doi.org/10.1101/2022.08.01.22278286

Add to Selected Citations
Real-life evaluation of a rapid antigen test (DPP® SARS-CoV-2 Antigen) for COVID-19 diagnosis of primary healthcare patients, in the context of the Omicron-dominant wave in Brazil
Matheus Filgueira Bezerra, Lilian Caroliny Amorim Silva, Rômulo Pessoa-e-Silva, Gisele Lino Soares, Filipe Zimmer Dezordi, Gustavo Barbosa de Lima, Raul Emídio de Lima, Tulio L. Campos, Cassia Docena, Anderson Bruno de Oliveira, Maira Galdino da Rocha Pitta, Francisco de Assis da Silva Santos, Michelly Pereira, Gabriel Luz Wallau, Marcelo Henrique Santos Paiva

medRxiv 2022.08.02.22278277; doi: https://doi.org/10.1101/2022.08.02.22278277

Add to Selected Citations
Cellular and humoral immunity towards parental SARS-CoV-2 and variants of concern after two doses of the NVX-CoV2373-vaccine in comparison to homologous BNT162b and mRNA1273 regimens
Franziska Hielscher, Tina Schmidt, Verena Klemis, Alexander Wilhelm, Stefanie Marx, Amina Abu-Omar, Laura Ziegler, Candida Guckelmus, Rebecca Urschel, Urban Sester, Marek Widera, Martina Sester

medRxiv 2022.08.02.22278342; doi: https://doi.org/10.1101/2022.08.02.22278342

Add to Selected Citations
Safety and efficacy of the two doses conjugated protein-based SOBERANA-02 COVID-19 vaccine and of a heterologous three-dose combination with SOBERANA-PLUS: double-blind, randomised, placebo-controlled phase 3 clinical trial
María Eugenia Toledo-Romaní, Mayra García-Carmenate, Carmen Valenzuela-Silva, Waldemar Baldoquín-Rodríguez, Marisel Martínez-Pérez, Meiby Rodríguez-González, Beatriz Paredes-Moreno, Ivis Mendoza-Hernández, Raúl González-Mujica, Oscar Samón-Tabio, Pablo Velazco-Villares, Juan Pablo Bacallao-Castillo, Ernesto Licea-Martín, Misladys Rodríguez-Ortega, Nuris Herrera-Marrero, Esperanza Caballero-González, Liudmila Egües-Torres, Reinaldo Duartes-González, Serguey García-Blanco, Suzette Pérez-Cabrera, Santos Huete-Ferreira, Kirenia Idalmis-Cisnero, Omayda Fonte-Galindo, Dania Meliá-Pérez, Ivonne Rojas-Remedios, Delaram Doroud, Mohammad Mehdi Gouya, Alireza Biglari, Patrick Van der Stuyft, Sonsire Fernández-Castillo, Yanet Climent-Ruiz, Yury Valdes-Balbín, Dagmar García-Rivera, Vicente Verez-Bencomo, the SOBERANA Phase 3 team

medRxiv 2021.10.31.21265703; doi: https://doi.org/10.1101/2021.10.31.21265703

Add to Selected Citations

Infectious Diseases (except HIV/AIDS)

Pages